vs

Side-by-side financial comparison of IMMUCELL CORP (ICCC) and Insight Molecular Diagnostics Inc. (IMDX). Click either name above to swap in a different company.

IMMUCELL CORP is the larger business by last-quarter revenue ($5.5M vs $1.1M, roughly 4.8× Insight Molecular Diagnostics Inc.). IMMUCELL CORP runs the higher net margin — -2.5% vs -2015.4%, a 2012.8% gap on every dollar of revenue. On growth, IMMUCELL CORP posted the faster year-over-year revenue change (-8.4% vs -23.4%). IMMUCELL CORP produced more free cash flow last quarter ($-1.8M vs $-7.0M). Over the past eight quarters, Insight Molecular Diagnostics Inc.'s revenue compounded faster (154.4% CAGR vs 3.9%).

ImmuCell Corp is a US-based animal health biotechnology company that develops, manufactures and markets innovative products for livestock, primarily dairy cattle. Its core offerings include preventive and therapeutic solutions for common bovine health issues such as mastitis, serving agricultural producers and veterinary providers across North America.

Quest Diagnostics Incorporated is an American clinical laboratory. A Fortune 500 company, Quest operates in the United States, Puerto Rico, Mexico, and Brazil. Quest also maintains collaborative agreements with various hospitals and clinics across the globe.

ICCC vs IMDX — Head-to-Head

Bigger by revenue
ICCC
ICCC
4.8× larger
ICCC
$5.5M
$1.1M
IMDX
Growing faster (revenue YoY)
ICCC
ICCC
+14.9% gap
ICCC
-8.4%
-23.4%
IMDX
Higher net margin
ICCC
ICCC
2012.8% more per $
ICCC
-2.5%
-2015.4%
IMDX
More free cash flow
ICCC
ICCC
$5.2M more FCF
ICCC
$-1.8M
$-7.0M
IMDX
Faster 2-yr revenue CAGR
IMDX
IMDX
Annualised
IMDX
154.4%
3.9%
ICCC

Income Statement — Q3 2025 vs Q4 2025

Metric
ICCC
ICCC
IMDX
IMDX
Revenue
$5.5M
$1.1M
Net Profit
$-139.7K
$-23.0M
Gross Margin
42.9%
42.5%
Operating Margin
0.4%
-2057.5%
Net Margin
-2.5%
-2015.4%
Revenue YoY
-8.4%
-23.4%
Net Profit YoY
80.1%
31.5%
EPS (diluted)
$-0.02
$-0.75

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ICCC
ICCC
IMDX
IMDX
Q4 25
$1.1M
Q3 25
$5.5M
$260.0K
Q2 25
$6.4M
$518.0K
Q1 25
$8.1M
$2.1M
Q4 24
$7.8M
$1.5M
Q3 24
$6.0M
$115.0K
Q2 24
$5.5M
$104.0K
Q1 24
$7.3M
$176.0K
Net Profit
ICCC
ICCC
IMDX
IMDX
Q4 25
$-23.0M
Q3 25
$-139.7K
$-10.9M
Q2 25
$501.9K
$-9.7M
Q1 25
$1.4M
$-6.7M
Q4 24
$-33.5M
Q3 24
$-701.7K
$-13.5M
Q2 24
$-1.5M
$-4.5M
Q1 24
$-437.9K
$-9.1M
Gross Margin
ICCC
ICCC
IMDX
IMDX
Q4 25
42.5%
Q3 25
42.9%
53.5%
Q2 25
43.7%
67.6%
Q1 25
41.6%
62.0%
Q4 24
36.5%
40.0%
Q3 24
26.3%
43.5%
Q2 24
22.5%
48.1%
Q1 24
31.6%
25.6%
Operating Margin
ICCC
ICCC
IMDX
IMDX
Q4 25
-2057.5%
Q3 25
0.4%
-4249.2%
Q2 25
8.8%
-1900.0%
Q1 25
13.9%
-318.0%
Q4 24
8.0%
-2262.9%
Q3 24
-9.6%
-11752.2%
Q2 24
-25.3%
-4453.8%
Q1 24
-4.1%
-5265.3%
Net Margin
ICCC
ICCC
IMDX
IMDX
Q4 25
-2015.4%
Q3 25
-2.5%
-4174.6%
Q2 25
7.8%
-1880.7%
Q1 25
17.9%
-312.0%
Q4 24
-2255.1%
Q3 24
-11.7%
-11733.0%
Q2 24
-28.0%
-4355.8%
Q1 24
-6.0%
-5186.9%
EPS (diluted)
ICCC
ICCC
IMDX
IMDX
Q4 25
$-0.75
Q3 25
$-0.02
$-0.34
Q2 25
$0.06
$-0.30
Q1 25
$0.16
$-0.26
Q4 24
$0.09
$-2.19
Q3 24
$-0.09
$-0.98
Q2 24
$-0.20
$-0.36
Q1 24
$-0.06
$-1.13

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ICCC
ICCC
IMDX
IMDX
Cash + ST InvestmentsLiquidity on hand
$3.9M
$11.6M
Total DebtLower is stronger
$9.5M
Stockholders' EquityBook value
$29.8M
$-31.5M
Total Assets
$45.7M
$25.8M
Debt / EquityLower = less leverage
0.32×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ICCC
ICCC
IMDX
IMDX
Q4 25
$11.6M
Q3 25
$3.9M
$18.7M
Q2 25
$24.3M
Q1 25
$31.0M
Q4 24
$3.8M
$8.6M
Q3 24
$3.4M
Q2 24
$1.3M
$9.3M
Q1 24
$960.3K
$5.6M
Total Debt
ICCC
ICCC
IMDX
IMDX
Q4 25
Q3 25
$9.5M
Q2 25
Q1 25
$8.7M
Q4 24
$9.0M
Q3 24
$9.4M
Q2 24
$9.8M
Q1 24
$10.2M
Stockholders' Equity
ICCC
ICCC
IMDX
IMDX
Q4 25
$-31.5M
Q3 25
$29.8M
$-9.2M
Q2 25
$29.9M
$1.1M
Q1 25
$29.0M
$10.2M
Q4 24
$27.5M
$-12.3M
Q3 24
$26.4M
$9.7M
Q2 24
$23.5M
$22.7M
Q1 24
$24.6M
$11.6M
Total Assets
ICCC
ICCC
IMDX
IMDX
Q4 25
$25.8M
Q3 25
$45.7M
$43.9M
Q2 25
$46.7M
$50.5M
Q1 25
$45.6M
$60.4M
Q4 24
$45.1M
$35.1M
Q3 24
$44.4M
$70.2M
Q2 24
$41.9M
$74.7M
Q1 24
$43.1M
$71.0M
Debt / Equity
ICCC
ICCC
IMDX
IMDX
Q4 25
Q3 25
0.32×
Q2 25
Q1 25
0.30×
Q4 24
0.33×
Q3 24
0.36×
Q2 24
0.42×
Q1 24
0.41×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ICCC
ICCC
IMDX
IMDX
Operating Cash FlowLast quarter
$-1.2M
$-5.5M
Free Cash FlowOCF − Capex
$-1.8M
$-7.0M
FCF MarginFCF / Revenue
-32.3%
-616.7%
Capex IntensityCapex / Revenue
10.8%
129.9%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$715.4K
$-25.4M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ICCC
ICCC
IMDX
IMDX
Q4 25
$-5.5M
Q3 25
$-1.2M
$-4.5M
Q2 25
$1.6M
$-6.3M
Q1 25
$1.6M
$-5.9M
Q4 24
$-3.1K
$-5.4M
Q3 24
$-639.3K
$-5.5M
Q2 24
$581.8K
$-6.0M
Q1 24
$418.5K
$-3.8M
Free Cash Flow
ICCC
ICCC
IMDX
IMDX
Q4 25
$-7.0M
Q3 25
$-1.8M
$-5.6M
Q2 25
$1.4M
$-6.6M
Q1 25
$1.2M
$-6.2M
Q4 24
$-199.3K
$-5.6M
Q3 24
$-727.7K
$-5.6M
Q2 24
$471.0K
$-6.2M
Q1 24
$348.1K
$-3.9M
FCF Margin
ICCC
ICCC
IMDX
IMDX
Q4 25
-616.7%
Q3 25
-32.3%
-2135.4%
Q2 25
22.4%
-1279.5%
Q1 25
15.4%
-288.4%
Q4 24
-2.6%
-374.5%
Q3 24
-12.1%
-4884.3%
Q2 24
8.6%
-5931.7%
Q1 24
4.8%
-2189.8%
Capex Intensity
ICCC
ICCC
IMDX
IMDX
Q4 25
129.9%
Q3 25
10.8%
403.8%
Q2 25
2.4%
67.4%
Q1 25
4.1%
14.4%
Q4 24
2.5%
14.4%
Q3 24
1.5%
75.7%
Q2 24
2.0%
183.7%
Q1 24
1.0%
13.6%
Cash Conversion
ICCC
ICCC
IMDX
IMDX
Q4 25
Q3 25
Q2 25
3.19×
Q1 25
1.09×
Q4 24
Q3 24
Q2 24
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons